Certara UK Limited

The principal activity of the Company in the year under review was that of the development and advancement of algorithms to simulate the absorption and disposition of drugs in virtual populations in order to predict pharmacokinetic and phar m acodynamics behaviour, including drug-to-drug interactions. The Company conducts its activities for a customer base of global phar m aceutical and biotechnology companies. In addition, consultancy services are offered on related topics. Workshops are held at various global locations to educate clients or potential clients on the science involved in model-informed drug development. The Company also provides licences to major academic and non-profit centres of excellence for both teaching and research purposes as well as to regulatory authorities.